OTC Markets Group Inc. (OTCM: OTCQX U.S. Premier) | OTC
Top 10 Most Recent News Articles
D-Wave Quantum Hit with Securities Fraud Lawsuit
A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...
Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss
Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...
Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact
A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...
Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms
Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...
Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026
A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...
Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives
Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...
Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data
Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...
Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly
Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...
Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path
New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...
Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake
Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...
Continue ReadingTop 5 Most Recently Viewed Articles
b1BANK Partners with Spiral to Enhance Community Banking Impact
Enhanced Financial Wellness through Partnership NEW YORK--Today, Spiral, a personalized banking platform, announced a significant partnership with b1BANK, established as a community-focused banking institution. Through this collaboration, the two organizations aim to enhance financial wellness for customers, leveraging b1BANK's dedication to innovative banking solutions...
Continue Reading
AM Best Explores Trends Influencing For-Hire Trucking Industry
Insights from AM Best's Latest Webinar on Trucking Trends Viewers can now delve into the highlights from the enlightening webinar hosted by AM Best, titled "For-Hire Trucking: The Risky Road Ahead." This event focused on the intricacies and challenges within the transportation-for-hire trucking sector, providing expert insights into risk management strategies and the...
Continue Reading
BitMart's Creative Campaign to Ignite Offline Crypto Engagement
Introducing the Fox Hunt Delivery Campaign BitMart, a leading global cryptocurrency exchange, is excited to announce the launch of the Fox Hunt Delivery Campaign, a unique initiative aimed at boosting cryptocurrency adoption through engaging offline activities. This campaign offers an exciting chance for participants to earn USDT rewards simply by introducing new users to...
Continue Reading
Trinity Capital Inc. Fuels Alt Platform's Growth with $40M Credit
Trinity Capital Inc. Supports Alt with Significant Credit Facility Trinity Capital Inc. (NASDAQ: TRIN), a prominent alternative asset manager, is thrilled to announce a groundbreaking agreement with Alt, providing up to $40 million through an asset-based revolving credit facility. This funding aims to bolster Alt's innovative marketplace tailored for trading card...
Continue Reading
Everest Medicines Achieves Record Revenue and Growth in 2024
Everest Medicines Achieves Remarkable Financial Success Everest Medicines, a groundbreaking biopharmaceutical company focused on innovative healthcare solutions, has reported remarkable financial results for the year ending December 31, 2024. With a robust revenue growth of 461%, the company stands out in the pharmaceutical industry, showcasing its resilience and dynamic...
Continue Reading